◀ Back to IGF1

IGF1 — IGFALS

Pathways - manually collected, often from reviews:

• Reactome Reaction: IGF1 → IGFALS (reaction) Janosi et al., J Biol Chem 1999*, Okabe et al., FEBS Lett 1999*, Gibson et al., Growth Horm IGF Res 1999, Twigg et al., Endocrinology 2000*, Belgorosky et al., Horm Res 1999*, Bond et al., J Endocrinol 2000, Angelloz-Nicoud et al., Growth Horm IGF Res 1998*, Galanis et al., J Endocrinol 2001*, Overgaard et al., J Biol Chem 2001, Firth et al., Endocrinology 2001*, Laursen et al., FEBS Lett 2001, Schneider et al., Biochem Biophys Res Commun 2001, Booth et al., Am J Physiol Endocrinol Metab 2002, Hoeflich et al., Cancer Res 2001, Baxter et al., J Clin Endocrinol Metab 2002, Mohan et al., J Endocrinol 2002, Firth et al., Endocr Rev 2002, Payet et al., Endocrinology 2003*, Baxter et al., J Biol Chem 1992*, Cohen et al., J Clin Endocrinol Metab 1992*, Payet et al., J Clin Endocrinol Metab 2004*, Choi et al., J Biochem Mol Biol 2004*, Yan et al., J Biol Chem 2004*, Holly et al., Neuroendocrinology 2006, Baxter et al., Proc Natl Acad Sci U S A 1989*, Arai et al., J Biol Chem 1994, Fowlkes et al., J Biol Chem 1994, Lee et al., J Clin Endocrinol Metab 1994*, Cohen et al., J Endocrinol 1994*, Lalou et al., Endocrinology 1994*, Fielder et al., Growth Regul 1994, Juul et al., J Clin Endocrinol Metab 1995, Angelloz-Nicoud et al., Endocrinology 1995*, Bach et al., J Biol Chem 1993, Cianfarani et al., Experientia 1993, Bach et al., Biochim Biophys Acta 1996, Rajah et al., Prog Growth Factor Res 1995, Angelloz-Nicoud et al., Growth Regul 1996*, Lalou et al., Horm Res 1996*, Twigg et al., J Biol Chem 1998*, Collett-Solberg et al., J Clin Endocrinol Metab 1998*, Twigg et al., J Biol Chem 1998*, Rajah et al., Am J Respir Cell Mol Biol 1999
• Reactome Reaction: IGF1 → IGFALS (direct_complex) Janosi et al., J Biol Chem 1999*, Twigg et al., Endocrinology 2000*, Belgorosky et al., Horm Res 1999*, Bond et al., J Endocrinol 2000, Galanis et al., J Endocrinol 2001*, Firth et al., Endocrinology 2001*, Baxter et al., J Clin Endocrinol Metab 2002, Mohan et al., J Endocrinol 2002, Firth et al., Endocr Rev 2002, Payet et al., Endocrinology 2003*, Baxter et al., J Biol Chem 1992*, Payet et al., J Clin Endocrinol Metab 2004*, Choi et al., J Biochem Mol Biol 2004*, Yan et al., J Biol Chem 2004*, Holly et al., Neuroendocrinology 2006, Baxter et al., Proc Natl Acad Sci U S A 1989*, Arai et al., J Biol Chem 1994, Juul et al., J Clin Endocrinol Metab 1995, Bach et al., J Biol Chem 1993, Cianfarani et al., Experientia 1993, Bach et al., Biochim Biophys Acta 1996, Twigg et al., J Biol Chem 1998*, Collett-Solberg et al., J Clin Endocrinol Metab 1998*, Twigg et al., J Biol Chem 1998*

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Biogrid Interaction: IGF1 — IGFALS (physical association, affinity chromatography technology) Ueki et al., Proc Natl Acad Sci U S A 2000*
• MIPS CORUM IGF1-IGFBP3-ALS complex: IGF1-IGFBP3-ALS complex complex (IGF1-IGFALS-IGFBP3) Lewitt et al., J Endocrinol 1998*
• IRef Corum Interaction: Complex of IGF1-IGFBP3-IGFALS (association, affinity chromatography technology) Lewitt et al., J Endocrinol 1998*
• IRef Hprd Interaction: IGF1 — IGFALS (in vivo) Ueki et al., Proc Natl Acad Sci U S A 2000*, Twigg et al., J Biol Chem 1998*
• IRef Ophid Interaction: IGF1 — IGFALS (aggregation, interologs mapping) Brown et al., Bioinformatics 2005

Text-mined interactions from Literome

Barreca et al., Growth Horm IGF Res 1998 (Sepsis) : By limiting the formation of the 150 kDa complex, this reduction in circulating ALS might contribute to the rapid decline in serum IGF-I observed in sepsis
Silha et al., Adv Exp Med Biol 2005 : Absence of human and also mouse ALS leads to decreased IGF-I levels in circulation and causes mild growth retardation
Kim et al., J Endocrinol 2006 : We conclude that the decline in plasma ALS after parturition is a consequence of hepatic GH resistance and contributes to the associated reduction of plasma IGF-I
Mucci et al., Cancer Epidemiol Biomarkers Prev 2010 (Prostatic Neoplasms) : The acid-labile subunit (ALS) acts in the insulin-like growth ( IGF ) system by binding circulating IGF-I in a ternary complex with binding protein ( IGFBP)-3 to prevent IGF-I from crossing the endothelial barrier
Baxter et al., J Biol Chem 1989 : Pure ALS formed a complex with BP-53 ( Ka approximately 5 x 10 ( 8 ) M-1 ), immunoprecipitable by anti-BP-53 antiserum, only in the presence of IGF-I or IGF-II
Scharf et al., Hepatology 1996 : Insulin, IGF-I , and GH increased ALS expression
Frystyk et al., Endocrinology 1998 : We describe a novel competitive assay for rat insulin-like growth factor (IGF) binding protein-3 ( rIGFBP-3 ) based on the ability of IGFBP-3 to form a ternary complex with the acid labile subunit (ALS) in the presence of IGF
Labarta et al., Clin Endocrinol (Oxf) 1997 (Growth Disorders) : The aims of this investigation were ( a ) to study the presence of immunoreactive forms of the acid-labile subunit (ALS) in different human biological fluids, ( b ) to define the age dependence of serum ALS in normal children and adults and ( c ) to compare the regulation of ALS by GH or IGF-I in children with GH deficiency ( GHD ) and GH receptor deficiency (GHRD) before and after 1 year of therapy with GH or IGF-I, respectively
Frystyk et al., Endocrinology 1998 : We have recently described a competitive binding assay for rat insulin-like growth factor binding protein-3 ( IGFBP-3 ) based on the ability of IGFBP-3 to form a ternary complex with the acid-labile subunit (ALS) in the presence of IGF-I